Corlanor FDA Approval History
Corlanor (ivabradine) is a hyperpolarization-activated cyclic nucleotide-gated channel blocker indicated for the treatment of chronic heart failure.
Development Timeline for Corlanor
|Apr 15, 2015||FDA Approves Corlanor (ivabradine) to Treat Heart Failure|
|Aug 27, 2014||FDA Grants Amgen Priority Review Designation For Ivabradine For The Treatment Of Chronic Heart Failure|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.